TY - JOUR
T1 - Mitochondrial Medicine
T2 - A Promising Therapeutic Option Against Various Neurodegenerative Disorders
AU - Almikhlafi, Mohannad A.
AU - Karami, Mohammed M.
AU - Jana, Ankit
AU - Alqurashi, Thamer M.
AU - Majrashi, Mohammed
AU - Alghamdi, Badrah S.
AU - Ashraf, Ghulam Md
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - Abnormal mitochondrial morphology and metabolic dysfunction have been observed in many neurodegenerative disorders (NDDs). Mitochondrial dysfunction can be caused by aberrant mi-tochondrial DNA, mutant nuclear proteins that interact with mitochondria directly or indirectly, or for unknown reasons. Since mitochondria play a significant role in neurodegeneration, mitochondria-targeted therapies represent a prosperous direction for the development of novel drug compounds that can be used to treat NDDs. This review gives a brief description of how mitochondrial abnormalities lead to various NDDs such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. We further explore the promising therapeutic effectiveness of mitochon-dria-directed antioxidants, MitoQ, MitoVitE, MitoPBN, and dimebon. We have also discussed the possibility of mitochondrial gene therapy as a therapeutic option for these NDDs.
AB - Abnormal mitochondrial morphology and metabolic dysfunction have been observed in many neurodegenerative disorders (NDDs). Mitochondrial dysfunction can be caused by aberrant mi-tochondrial DNA, mutant nuclear proteins that interact with mitochondria directly or indirectly, or for unknown reasons. Since mitochondria play a significant role in neurodegeneration, mitochondria-targeted therapies represent a prosperous direction for the development of novel drug compounds that can be used to treat NDDs. This review gives a brief description of how mitochondrial abnormalities lead to various NDDs such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. We further explore the promising therapeutic effectiveness of mitochon-dria-directed antioxidants, MitoQ, MitoVitE, MitoPBN, and dimebon. We have also discussed the possibility of mitochondrial gene therapy as a therapeutic option for these NDDs.
KW - Alzheimer’s disease
KW - amyotrophic lateral sclerosis
KW - gene therapy
KW - Huntington’s disease
KW - mitochondrial dysfunction
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=85140987505&partnerID=8YFLogxK
U2 - 10.2174/1570159X20666220830112408
DO - 10.2174/1570159X20666220830112408
M3 - Review article
C2 - 36043795
AN - SCOPUS:85140987505
SN - 1570-159X
VL - 21
SP - 1165
EP - 1183
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 5
ER -
